Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Rhea-AI Summary
Neurocrine Biosciences (NBIX) has announced a new $500 million share repurchase program, following the completion of a $300 million accelerated repurchase program from October 2024 to February 2025. The new authorization allows for various repurchase methods, including open-market transactions, privately negotiated deals, and accelerated share repurchases.
The company's Board Chairman, William Rastetter, stated this decision aligns with their capital allocation strategy, which balances revenue growth through investment in commercial products INGREZZA and CRENESSITY, advancement of R&D pipeline, and returning capital to shareholders.
Positive
- Authorization of new $500M share repurchase program
- Successful completion of previous $300M repurchase program
- Strong capital allocation strategy balancing growth investments and shareholder returns
- Demonstrates financial strength and confidence in company's future
Negative
- Significant cash outlay may reduce funds available for R&D and business development
- Market conditions may affect actual repurchase execution
News Market Reaction
On the day this news was published, NBIX gained 3.94%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."
Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to potential share repurchases and the future performance of Neurocrine Biosciences. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements, include but are not limited to the following: whether we will be able to consummate the contemplated share repurchases in the amount authorized or at all; constraints, volatility, or disruptions in the capital markets or other factors affecting our ability to enter into or complete share repurchases; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general; risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-board-of-directors-authorizes-500-million-share-repurchase-program-302382162.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
How much is NBIX's new share repurchase program worth?
When did NBIX complete its previous share repurchase program?
What methods will NBIX use for the share repurchases?
How does the share repurchase program fit into NBIX's capital strategy?
What is the total value of NBIX's recent share repurchase programs?
